

BIOSANTE PHARMACEUTICALS INC

Form 8-K

November 08, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of report (Date of earliest event reported): **November 8, 2012**

**BIOSANTE PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-31812**  
(Commission  
File Number)

**58-2301143**  
(I.R.S. Employer  
Identification Number)

**111 Barclay Boulevard**

**Lincolnshire, Illinois**  
(Address of principal executive offices)

**60069**  
(Zip Code)

## Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

Registrant's telephone number, including area code: **(847) 478-0500**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Section 2 Financial Information**

**Item 2.02. Results of Operations and Financial Condition.**

On November 8, 2012, BioSante Pharmaceuticals, Inc. publicly announced its financial results for the third quarter of 2012. For further information, please refer to the news release attached hereto as Exhibit 99.1, which is incorporated by reference herein.

**Section 8 Other Events**

**Item 8.01. Other Events.**

On November 8, 2012, BioSante provided an update regarding its proposed merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals.

A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Section 9 Financial Statements and Exhibits**

**Item 9.01. Financial Statements and Exhibits.**

(d) *Exhibits.*

Exhibit No.	Description
99.1	News Release issued November 8, 2012

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSANTE PHARMACEUTICALS, INC.**

By: */s/ Phillip B. Donenberg*  
Phillip B. Donenberg  
*Senior Vice President of Finance, Chief*  
*Financial Officer and Secretary*

Dated: November 8, 2012

**BIOSANTE PHARMACEUTICALS, INC.**

**FORM 8-K**

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>	<b>Method of Filing</b>
99.1	News Release issued November 8, 2012	Filed herewith